• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Dermatology Life Quality Indexprovides different information from PASI

Article

Washington - The Dermatology Life Quality Index (DLQI) is a widely used and validated measure of patient-reported outcomes in psoriasis. Unlike the Psoriasis Area Severity Index (PASI) score, a well-established measure of a patient's disease activity where each area of the body is weighted proportionally to the surface area covered, the DLQI is more heavily influenced by areas of the body that are readily visible, such as the head and lower extremities. "Therefore, the DLQI may provide information regarding outcomes beyond that described by the PASI score," said Alexa B. Kimball, M.D., M.P.H., assistant professor of dermatology at Stanford University.

Related Videos
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo
© 2024 MJH Life Sciences

All rights reserved.